ThromboGenics NV, which is developing treatments for eye disease, vascular disease and cancer, has raised €3.1 million as the result of the exercise of warrants by a number of employees. The move created 597,000 new shares.
The company also announced that it has completed the merger of ThromboGenics NV with its UK subsidiary ThromboGenics Ltd, streamlining the corporate structure and optimising tax management.
Follow where the public and private R&I money is going and which collaborative opportunities you can pursue.
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening.
Sign up for the Funding Newswire
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
